John Pagel, MD, PhD, Discusses Dosing Regimens and Toxicity Associated With Zanubrutinib and Zandelisib
Zanubrutinib and zandelisib combination appears to be a well-tolerated regimen for the treatment of B-cell malignancies, according to early study results.
Large Meta-Analysis of Additional Trastuzumab for Early HER2+ Breast Cancer Confirms Large Treatment Benefit Regardless of Baseline Characteristics
A large meta-analysis showed a one-third reduction in recurrence or death in patients with HER2-positive early breast cancer with 1 year of trastuzumab added to chemotherapy, confirming the benefit of this therapy across baseline characteristics.
Encouraging Overall Response Rate Reported With Domvanalimab-Combinations in Non-Small Cell Lung Cancer
A 3-arm randomized study indicated that domvanalimab-based combinations yielded a promising overall response rate for patients with metastatic non–small cell lung cancer with a PD-L1 status of 50% or more.
CAR T-Cell Therapy P-PSMA-101 Demonstrates Promising Early Data in mCRPC
Preliminary findings indicate that P-PSMA-101, a CAR T-cell therapy, may be efficacious in patient with metastatic castration-resistant prostate cancer.
Vincristine/Dexamethasone Pulse Therapy May be Omitted After 1 Year of Treatment in Pediatric Acute Lymphoblastic Leukemia
Pediatric patients with low-risk acute lymphoblastic leukemia may be able to omit treatment with vincristine and dexamethasone pulse therapy after the first year of treatment.
Survival Benefit of Autologous HSCT in Mantle Cell Lymphoma Confirmed in Post Hoc Analysis
Autologous hematopoietic stem-cell transplantation appears to improved survival compared with interferon alfa maintenance therapy for patients with previously untreated mantle cell lymphoma.
Poor Health-Related Quality of Life May be Associated With Increased Mortality Among Breast Cancer Survivors
A number of prognostic and treatment related factors have been found to impact health-related quality of life among survivors of breast cancer.
COVID-19 Antibodies Are Similar for Those With Solid Tumors Compared With Those Without 6-Months After the Second Dose
Patients with cancer and those without cancer had similar serologic results 6-months after receiving their second BNT162b2 vaccine.
Robust, Long-Lasting Responses Observed With VenDd and VenDVd in the Treatment of Relapsed/Refractory Multiple Myeloma
Patients with relapsed or refractory multiple myeloma with or without t(11;14) experienced promising responses after being treated with venetoclax plus daratumumab and dexamethasone, as well as venetoclax plus daratumumab, dexamethasone, and bortezomib.
Romyelocel-L Lowers Infection Risk During Induction Chemotherapy in Acute Myeloid Leukemia
The risk of infection during induction chemotherapy decreased among patients with acute myeloid leukemia treated with romyelocel-L.
Certain Genomic Pathways of Gut Microbiome Significantly Associated With Survival in Nivolumab-Treated Patients With Gastric/GEJ Cancer
Data from patients with gastric or gastroesophageal junction cancers who were treated with nivolumab showed that effects in the genomic pathways of the gut microbiome may be significantly associated with survival.
FDA Approves Zanubrutinib for the Treatment Waldenströms Macroglobulinemia
Zanubrutinib has been approved by the FDA for the treatment of patients with Waldenströms macroglobulinemia based on the results of the phase 3 ASPEN trial.
High Intensity Interval Training Helped Men With Localized Prostate Cancer Achieve Increased Cardiorespiratory Fitness
High intensity interval training yielded decreased prostate-specific antigen levels and velocity, as well as lowering prostate cell growth in men with localized prostate cancer.
Preoperative Chemoradiotherapy Plus Avelumab Elicits Promising Activity for Locally Advanced Rectal Cancer
The combination of standard chemoradiotherapy plus avelumab demonstrated clinical activity while maintaining a tolerable safety profile for patients with locally advanced rectal cancer.
Notable Declines Observed in Diagnosis of Common Solid Malignancies During the First Year of the COVID-19 Pandemic
New diagnoses of common cancer types declined significantly during the first year of the COVID-19 pandemic.
Gemcitabine Plus Cisplatin Provides Survival Benefit Over Fluorouracil Plus Cisplatin in Advanced Nasopharyngeal Carcinoma
Patients with advanced nasopharyngeal carcinoma and who were treated with gemcitabine plus cisplatin experienced a longer overall survival and improved progression-free survival vs fluorouracil plus cisplatin.
Latina Breast Cancer Survivors Are Less Likely to Seek Psychosocial Services Than Non-Latina Women
Latina breast cancer survivors are less likely to seek counseling due to concerns that the counselor will not understand their values or have linguistic challenges.
FDA Converts Indication for Pembrolizumab as Frontline Therapy for Bladder Cancer to Full Approval
The FDA has granted a full approval to pembrolizumab for the treatment of platinum-ineligible patients with urothelial cancer.
Post-Transplant Cyclophosphamide Appears to be a Promising Prophylactic Treatment Against GvHD in Acute Lymphoblastic Leukemia
Compared with anti-thymocyte globulin, post-transplant cyclophosphamide appears to more successfully prevent graft-versus-host disease in patients with acute lymphoblastic leukemia, resulting in a lower incidence of relapse and improved survival.
Real-World Studies Show Insufficiency For Informing Clinical, Reimbursement Decisions of Novel Cancer Drugs
Low study quality was determined in an analysis of real-world studies across multiple drug indications in cancer.
Primary Survivorship Care In Patients With Breast Cancer and Other Malignancies May Be Feasible Versus Secondary Care
Survivorship incorporated into primary cancer care may be more cost effective and lead to better clinical and patient-reported outcomes in patients with breast cancer and other malignancies.
ASTRO Publishes Clinical Guidelines for Radiotherapy in Soft Tissue Sarcoma
A new set of guidelines for utilizing radiation therapy in adult patients with soft tissue sarcoma has been published by the American Society for Radiation Oncology.
John Pagel, MD, PhD, on Promising Responses Seen With Zanubrutinib Plus Zandelisib for B-Cell Malignancies
Patients with relapsed or regractory B-cell malignancies who were treated with zanubrutinib and zandelisib demonstrated high response rates across several treatment cohorts.
Extended Interval Dosing With Zoledronic Acid in Metastatic SCLC and NSCLC Appears to Be a Safe and Reasonable Option
Patients with non–small cell lung cancer and small-cell lung cancer with bone metastases may benefit from extended dosing with zoledronic acid.
Minority Populations With Aggressive B-Cell Lymphoma Achieved Equitable Estimated Survival Through Equal Access to Care and Nurse Navigation
Minority patients with aggressive B-cell lymphoma experienced equitable outcomes through more accessible care and the use of the nurse navigators.
NCCN Issues Updated Guidelines Regarding Third COVID-19 Vaccine Booster for Those With Cancer
Updates to the National Comprehensive Cancer Network guidelines on the COVID-19 vaccine for patients with cancer indicate that this group should be prioritized for a third dose.
Extending the Use of Adjuvant Zoledronate Past 2 Years Does Not Improve Prognosis in High-Risk Early Breast Cancer
Patients with high-risk early breast cancer who received zoledronate for over 2 years did not experience an improvement in prognosis.
Oncology Peer Review On-The-Go: Two Experts Review Important R/R DLBCL Treatment Decisions and Data
Gilles Salles, MD, PhD, and Kami Maddocks, MD, discuss relapsed/refractory diffuse large B-cell lymphoma therapeutic options and important data from the L-MIND trial.
Hypofractionated Image-Guided Versus Conventionally Fractionated Radiotherapy Shows No Treatment Advantage in NSCLC With Poor Performance Status
The use of hypofractionated image-guide radiotherapy was not found to improve overall survival for patients with non–small cell lung cancer and poor performance status versus conventional fractionated radiation techniques.
OncView™ Podcast: Updates in Therapies for Relapsed/Refractory Follicular Lymphoma
This special episode of “Oncology Peer Review On-The-Go” includes a discussion on relapsed/refractory follicular lymphoma with Javier Munoz, MD, MS, FACP.
